January – March 2018
Lund, Sweden, 08.00 CET, 4 May 2018 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Q1 Interim Report – January – March 2018.
BEST QUARTER EVER IN EUROPE
JANUARY – MARCH 2018
- Net Sales amounted to SEK 31.1million (32.5), a decrease of 4%. Sales were flat in constant currency terms and were 15.2% higher than Q4 2017
- Gross margin of 82.1% (88.8)
- Operating loss of SEK ‐33.1 million (‐27.4)
- Earnings per share, before and after dilution was SEK ‐0.67 (‐1.07)
JANUARY – MARCH 2018
- Emil Billbäck started as new CEO on 1 March, replacing Richard Davies
- Positive CERAMENT® G clinical data for the treatment of bone infections were presented at the British Limb Reconstruction Society (BLRS) Meeting 2018, in March
- First sales to 3 of the top 20 trauma centers in Italy, via Citieffe, our new distributor
- BONESUPPORT repaid an outstanding loan from Kreos Capital amounting to SEK 93.3 million (EUR 9.5 million)
Emil Billbäck, CEO of BONESUPPORT, said: “The first quarter in 2018 was in line with our expectations and the strong market penetration in Europe continued and delivered its best quarter ever. The sales in the US improved significantly from the last quarter in 2017 despite negative impact from Zimmer Biomet’s logistic problems.”
The full Report is available by clicking on the links below:
Outside the US: https://www.bonesupport.com/en-eu/financial-reports-inv/
The report will be available on BONESUPPORT’s website from 08:00 am CET the same day and the presentation from the webcast will be uploaded during the day on 4 May.
Conference Call/Webcast Details
The Company will host a conference call and an online presentation at 10.00am CET today.
The dial-in numbers for the conference call are:
UK: +44 2030089810
SE: +46 856642669
US: +1 8557532236
The presentation will also be webcast and can be accessed from the following web address:
Hosts: Emil Billbäck, CEO, and Björn Westberg, CFO
BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.
BONESUPPORT’s marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary CERAMENT technology platform.
The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.
BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.
The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.
BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at bonesupport.com
*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States
BONESUPPORT™ and CERAMENT® are registered trademarks.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Björn Westberg, CFO
+46 (0) 46 286 53 60
Citigate Dewe Rogerson
Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews
+44 (0)20 7282 1022
This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00am CET on 4 February 2018.